 -AGTC executives will address critical success factors in gene therapy manufacturing and the value of the patient perspective in gene therapy development --- GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 16, 2021 GLOBE NEWSWIRE -- Applied Genetic Technologies Corporation Nasdaq: AGTC, a biotechnology company conducting human clinical trials of adeno-associated virus AAV-based gene therapies for the treatment of rare diseases, today announced that Dave Knop, Vice President of Process Development, and Jill Dolgin, PharmD, Executive Director of Patient Advocacy, will present at the 4th Annual Gene Therapy for Rare Disorders digital event taking place February 22-25, 2021. 